Currently, Wilms’ tumor 1 (WT1), preferentially expressed antigen in melanoma (PRAME), and minor histocompatibility antigens (MiHA) have been the only AML antigens targeted using TCR-T cells in a clinical setting. This evidence concerns the gene WT1 and acute myeloid leukemia.